Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:MYCBP2-SPPL2A (FusionGDB2 ID:56210)

Fusion Gene Summary for MYCBP2-SPPL2A

Fusion gene summary

Fusion gene information	Fusion gene name: MYCBP2-SPPL2A
	Fusion gene ID: 56210
		Hgene	Tgene
	Gene symbol	MYCBP2	SPPL2A
	Gene ID	23077	84888
	Gene name	MYC binding protein 2	signal peptide peptidase like 2A
	Synonyms	Myc-bp2\|PAM\|PHR1\|Phr	IMP3\|PSL2
	Cytomap	13q22.3	15q21.2
	Type of gene	protein-coding	protein-coding
	Description	E3 ubiquitin-protein ligase MYCBP2HighwireMYC binding protein 2, E3 ubiquitin protein ligasePAM/Highwire/RPM-1 protein 1RING-type E3 ubiquitin transferase MYCBP2myc-binding protein 2pam/highwire/rpm-1 proteinprotein associated with Myc	signal peptide peptidase-like 2AIMP-3SPP-like 2Aintramembrane cleaving proteaseintramembrane protease 3presenilin-like protein 2
	Modification date	20200313	20200313
	UniProtAcc	O75592	Q8TCT8
	Ensembl transtripts involved in fusion gene	ENST00000357337, ENST00000407578, ENST00000544440, ENST00000360084, ENST00000482517,	ENST00000559293, ENST00000261854,
Fusion gene scores	* DoF score	14 X 16 X 8=1792	11 X 9 X 7=693
	# samples	15	11
	** MAII score	log2(15/1792*10)=-3.57853623156172 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(11/693*10)=-2.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: MYCBP2 [Title/Abstract] AND SPPL2A [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	MYCBP2(77661619)-SPPL2A(51028937), # samples:1
Anticipated loss of major functional domain due to fusion event.	MYCBP2-SPPL2A seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MYCBP2	GO:0016567	protein ubiquitination	29643511
Hgene	MYCBP2	GO:0031398	positive regulation of protein ubiquitination	20534529
Tgene	SPPL2A	GO:0006509	membrane protein ectodomain proteolysis	16829951\|17965014
Tgene	SPPL2A	GO:0031293	membrane protein intracellular domain proteolysis	16829951\|17557115
Tgene	SPPL2A	GO:0033619	membrane protein proteolysis	2313285

Fusion gene breakpoints across MYCBP2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across SPPL2A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	THCA	TCGA-EM-A3O3-01A	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-

Top

Fusion Gene ORF analysis for MYCBP2-SPPL2A

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
5CDS-intron	ENST00000357337	ENST00000559293	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
5CDS-intron	ENST00000407578	ENST00000559293	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
5CDS-intron	ENST00000544440	ENST00000559293	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
Frame-shift	ENST00000407578	ENST00000261854	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
Frame-shift	ENST00000544440	ENST00000261854	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
In-frame	ENST00000357337	ENST00000261854	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
intron-3CDS	ENST00000360084	ENST00000261854	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
intron-3CDS	ENST00000482517	ENST00000261854	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
intron-intron	ENST00000360084	ENST00000559293	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-
intron-intron	ENST00000482517	ENST00000559293	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000357337

MYCBP2

chr13

77661619

ENST00000261854

SPPL2A

chr15

51028937

12175

10854

10865

3592

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000357337	ENST00000261854	MYCBP2	chr13	77661619	-	SPPL2A	chr15	51028937	-	0.000172364	0.9998276

Top

Fusion Genomic Features for MYCBP2-SPPL2A

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for MYCBP2-SPPL2A

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:77661619/chr15:51028937)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
MYCBP2 O75592	SPPL2A Q8TCT8
FUNCTION: Atypical E3 ubiquitin-protein ligase which specifically mediates ubiquitination of threonine and serine residues on target proteins, instead of ubiquitinating lysine residues (PubMed:29643511). Shows esterification activity towards both threonine and serine, with a preference for threonine, and acts via two essential catalytic cysteine residues that relay ubiquitin to its substrate via thioester intermediates (PubMed:29643511). Interacts with the E2 enzymes UBE2D1, UBE2D3, UBE2E1 and UBE2L3 (PubMed:18308511, PubMed:29643511). Plays a key role in neural development, probably by mediating ubiquitination of threonine residues on target proteins (Probable). Involved in different processes such as regulation of neurite outgrowth, synaptic growth, synaptogenesis and axon degeneration (By similarity). Required for the formation of major central nervous system axon tracts (By similarity). Required for proper axon growth by regulating axon navigation and axon branching: acts by regulating the subcellular location and stability of MAP3K12/DLK (By similarity). Required for proper localization of retinogeniculate projections but not for eye-specific segregation (By similarity). Regulates axon guidance in the olfactory system (By similarity). Involved in Wallerian axon degeneration, an evolutionarily conserved process that drives the loss of damaged axons: acts by promoting destabilization of NMNAT2, probably via ubiquitination of NMNAT2 (By similarity). Catalyzes ubiquitination of threonine and/or serine residues on NMNAT2, consequences of threonine and/or serine ubiquitination are however unknown (PubMed:29643511). Regulates the internalization of TRPV1 in peripheral sensory neurons (By similarity). Mediates ubiquitination and subsequent proteasomal degradation of TSC2/tuberin (PubMed:18308511, PubMed:27278822). Independently of the E3 ubiquitin-protein ligase activity, also acts as a guanosine exchange factor (GEF) for RAN in neurons of dorsal root ganglia (PubMed:26304119). May function as a facilitator or regulator of transcriptional activation by MYC (PubMed:9689053). Acts in concert with HUWE1 to regulate the circadian clock gene expression by promoting the lithium-induced ubiquination and degradation of NR1D1 (PubMed:20534529). {ECO:0000250\|UniProtKB:Q7TPH6, ECO:0000269\|PubMed:18308511, ECO:0000269\|PubMed:20534529, ECO:0000269\|PubMed:26304119, ECO:0000269\|PubMed:27278822, ECO:0000269\|PubMed:29643511, ECO:0000269\|PubMed:9689053}.	FUNCTION: Intramembrane-cleaving aspartic protease (I-CLiP) that cleaves type II membrane signal peptides in the hydrophobic plane of the membrane. Functions in FASLG, ITM2B and TNF processing (PubMed:16829952, PubMed:16829951, PubMed:17557115, PubMed:17965014). Catalyzes the intramembrane cleavage of the anchored fragment of shed TNF-alpha (TNF), which promotes the release of the intracellular domain (ICD) for signaling to the nucleus (PubMed:16829952). Also responsible for the intramembrane cleavage of Fas antigen ligand FASLG, which promotes the release of the intracellular FasL domain (FasL ICD) (PubMed:17557115). May play a role in the regulation of innate and adaptive immunity (PubMed:16829952). Catalyzes the intramembrane cleavage of the simian foamy virus envelope glycoprotein gp130 independently of prior ectodomain shedding by furin or furin-like proprotein convertase (PC)-mediated cleavage proteolysis (PubMed:23132852). {ECO:0000269\|PubMed:16829951, ECO:0000269\|PubMed:16829952, ECO:0000269\|PubMed:17557115, ECO:0000269\|PubMed:17965014, ECO:0000269\|PubMed:23132852}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

103_126

3587

4641.0

Compositional bias

Lys-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

2720_2844

3587

4641.0

Compositional bias

Ser-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

3194_3215

3587

4641.0

Compositional bias

Lys-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

3262_3293

3587

4641.0

Compositional bias

Note=Gly-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

766_814

3587

4641.0

Compositional bias

Cys-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

103_126

3587

4641.0

Compositional bias

Lys-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

2720_2844

3587

4641.0

Compositional bias

Ser-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

3194_3215

3587

4641.0

Compositional bias

Lys-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

3262_3293

3587

4641.0

Compositional bias

Note=Gly-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

766_814

3587

4641.0

Compositional bias

Cys-rich

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

1235_1386

3587

4641.0

Region

PHR domain 1

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

1726_1884

3587

4641.0

Region

PHR domain 2

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

2022_2550

3587

4641.0

Region

RAE1 binding

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

1235_1386

3587

4641.0

Region

PHR domain 1

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

1726_1884

3587

4641.0

Region

PHR domain 2

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

2022_2550

3587

4641.0

Region

RAE1 binding

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

1010_1066

3587

4641.0

Repeat

RCC1 5

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

2341_2443

3587

4641.0

Repeat

Filamin

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

600_655

3587

4641.0

Repeat

RCC1 1

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

699_755

3587

4641.0

Repeat

RCC1 2

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

907_957

3587

4641.0

Repeat

RCC1 3

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

958_1008

3587

4641.0

Repeat

RCC1 4

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

1010_1066

3587

4641.0

Repeat

RCC1 5

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

2341_2443

3587

4641.0

Repeat

Filamin

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

600_655

3587

4641.0

Repeat

RCC1 1

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

699_755

3587

4641.0

Repeat

RCC1 2

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

907_957

3587

4641.0

Repeat

RCC1 3

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

958_1008

3587

4641.0

Repeat

RCC1 4

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

463_465

244

521.0

Motif

Note=PAL

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

495_498

244

521.0

Motif

Note=YXXo lysosomal targeting motif

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

242_247

244

521.0

Topological domain

Lumenal

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

269_285

244

521.0

Topological domain

Cytoplasmic

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

307_311

244

521.0

Topological domain

Lumenal

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

333_340

244

521.0

Topological domain

Cytoplasmic

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

362_399

244

521.0

Topological domain

Lumenal

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

421_437

244

521.0

Topological domain

Cytoplasmic

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

459_460

244

521.0

Topological domain

Lumenal

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

482_520

244

521.0

Topological domain

Cytoplasmic

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

248_268

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

286_306

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

312_332

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

341_361

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

400_420

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

438_458

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

461_481

244

521.0

Transmembrane

Helical

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

3719_3897

3587

4641.0

Domain

DOC

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

3719_3897

3587

4641.0

Domain

DOC

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

4539_4676

3587

4641.0

Region

Tandem cysteine domain

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

4539_4676

3587

4641.0

Region

Tandem cysteine domain

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000357337

4428_4479

3587

4641.0

Zinc finger

RING-type%3B atypical

Hgene

MYCBP2

chr13:77661619

chr15:51028937

ENST00000544440

4428_4479

3587

4641.0

Zinc finger

RING-type%3B atypical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

63_151

244

521.0

Domain

Note=PA

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

194_220

244

521.0

Topological domain

Cytoplasmic

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

26_172

244

521.0

Topological domain

Lumenal

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

173_193

244

521.0

Transmembrane

Helical

Tgene

SPPL2A

chr13:77661619

chr15:51028937

ENST00000261854

221_241

244

521.0

Transmembrane

Helical

Top

Fusion Gene Sequence for MYCBP2-SPPL2A

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>56210_56210_1_MYCBP2-SPPL2A_MYCBP2_chr13_77661619_ENST00000357337_SPPL2A_chr15_51028937_ENST00000261854_length(transcript)=12175nt_BP=10854nt
GGCGGCGGCAGTGGCGGCACCGCCTCCTCCTCACATTCCCGGGGTGGCGGGGTTAGATGAGCGGCCCCAGTAGCGGCGCCGGGGGCGCTG
TTCATGCCGGTTCCCGACGGCTCCGTGGCTGCTGCGGGGCTGGGGCTGGGGCTACCCGCCGCGGACTCCCGGGGTCACTACCAGCTGCTG
CTGTCAGGCCGGGCCCTGGCCGACCGCTACCGGAGGATTTATACCGCTGCGCTCAATGACAGGGACCAGGGGGGCGGCAGCGCTGGACAC
CCAGCCTCCAGGAATAAGAAAATTTTAAATAAGAAGAAATTGAAAAGAAAACAGAAGAGCAAATCAAAAGTGAAGACAAGAAGCAAGTCT
GAAAACTTAGAGAATACAGTAATCATACCAGATATCAAACTACATAGCAATCCTTCTGCTTTCAATATTTACTGTAATGTACGCCATTGC
GTTCTGGAATGGCAGAAAAAGGAAATATCATTGGCAGCCGCATCTAAGAACTCTGTGCAGAGTGGAGAATCAGATAGTGATGAAGAAGAG
GAATCCAAAGAGCCCCCTATCAAGCTTCCAAAGATTATTGAGGTTGGCCTTTGTGAAGTTTTTGAATTGATCAAAGAGACACGATTTTCT
CATCCATCCCTGTGTCTCAGGAGTCTCCAAGCCCTGCTCAACGTGCTGCAGGGCCAGCAGCCAGAAGGCCTCCAGTCTGAGCCACCTGAG
GTCCTAGAGTCTCTCTTCCAGCTTCTTTTGGAAATCACCGTTCGAAGTACTGGGATGAATGACAGCACAGGACAGTCCTTAACAGCACTT
TCCTGTGCTTGCCTCTTTAGTCTGGTGGCTTCTTGGGGAGAAACAGGAAGGACACTTCAGGCCATCTCTGCTATCCTCACCAACAATGGA
AGCCATGCTTGCCAAACTATTCAGGTGCCAACAATTCTAAATTCGCTACAGAGAAGTGTACAAGCAGTTTTGGTGGGAAAAATTCAAATT
CAGGACTGGTTTAGTAATGGCATTAAGAAAGCAGCTTTAATGCACAAGTGGCCATTAAAAGAAATATCTGTTGATGAAGATGACCAATGT
CTACTTCAGAATGATGGATTTTTTCTTTATCTATTATGCAAGGATGGATTATATAAAATAGGCTCTGGATACAGTGGAACAGTTAGGGGC
CATATATACAATTCTACATCCCGTATTAGAAACAGAAAAGAAAAAAAGTCTTGGTTAGGGTATGCTCAGGGTTATTTATTATATAGAGAT
GTGAATAACCACAGCATGACAGCCATAAGGATAAGCCCTGAAACACTGGAGCAAGATGGTACTGTGATGTTACCAGATTGCCACACTGAA
GGTCAAAATATTTTATTCACTGATGGAGAATATATTAATCAGATAGCTGCTTCAAGAGATGATGGCTTTGTTGTCAGAATATTTGCCACA
AGCACTGAACCTGTTCTACAGCAAGAATTGCAACTTAAACTGGCTAGAAAATGCTTACATGCCTGTGGTATCTCACTATTCGATCTGGAA
AAGGACTTGCATATTATAAGTACAGGATTTGATGAGGAGTCAGCAATTCTTGGTGCAGGACGAGAGTTTGCGCTAATGAAAACAGCAAAT
GGAAAGATATATTACACTGGCAAATACCAGAGTCTTGGAATCAAACAAGGTGGTCCTTCAGCAGGAAAATGGGTTGAGCTACCAATTACA
AAATCTCCAAAGATAGTACACTTCTCAGTTGGACACGATGGCTCTCACGCCCTTTTAGTTGCAGAAGATGGGAGCATATTCTTTACAGGA
TCTGCTAGTAAAGGAGAAGATGGAGAATCAACTAAGAGCAGACGGCAATCCAAACCTTATAAACCTAAAAAGATAATTAAGATGGAAGGA
AAGATTGTGGTATATACAGCCTGCAATAATGGAAGTAGTTCTGTTATTTCTAAAGATGGAGAACTCTACATGTTTGGAAAAGATGCCATT
TACTCTGATAGTTCAAGTTTGGTAACTGATTTGAAGGGCCATTTTGTAACTCAGGTAGCTATGGGCAAAGCTCACACTTGTGTTTTAATG
AAGAATGGAGAGGTGTGGACATTTGGTGTAAATAATAAAGGACAGTGTGGACGAGATACTGGTGCCATGAACCAAGGTGGGAAAGGGTTT
GGAGTTGAAAATATGGCAACAGCAATGGATGAAGACCTGGAAGAAGAACTAGATGAAAAAGATGAGAAGTCTATGATGTGCCCTCCAGGC
ATGCACAAATGGAAGCTGGAGCAGTGCATGGTTTGCACTGTCTGTGGAGACTGTACAGGTTATGGAGCCAGCTGTGTCAGTAGTGGACGG
CCAGACAGAGTCCCCGGAGGGATCTGTGGTTGTGGTTCCGGAGAATCTGGTTGTGCTGTGTGTGGATGTTGCAAGGCCTGTGCAAGAGAG
TTAGATGGTCAAGAGGCAAGACAAAGAGGAATTCTTGATGCAGTGAAAGAAATGATACCTTTAGATCTTCTTTTAGCTGTCCCAGTGCCC
GGGGTTAACATTGAAGAACACCTTCAGTTACGACAAGAAGAAAAACGGCAACGTGTAATCAGAAGGCACAGATTAGAGGAAGGAAGAGGC
CCCCTTGTATTTGCTGGTCCTATTTTTATGAACCATCGAGAACAGGCTCTAGCCAGACTCAGATCCCATCCAGCACAGCTAAAGCATAAA
CGGGACAAGCACAAAGATGGAAGTGGAGAAAGAGGCGAAAAGGATGCAAGCAAAATCACAACATACCCTCCAGGCTCTGTGCGATTTGAC
TGTGAGCTCCGGGCAGTCCAAGTCAGCTGTGGATTTCACCATTCAGTGGTTTTAATGGAAAATGGAGATGTCTATACATTTGGTTATGGG
CAGCATGGGCAGCTAGGACATGGAGATGTCAACTCCAGGGGATGTCCCACTCTTGTTCAAGCATTGCCAGGCCCTAGCACACAAGTCACT
GCAGGCAGCAACCATACGGCAGTACTTTTAATGGATGGACAGGTCTTCACATTTGGAAGTTTTTCTAAAGGACAACTGGGCAGACCAATT
TTGGATGTGCCATATTGGAATGCAAAGCCAGCTCCCATGCCTAACATTGGATCAAAATATGGAAGAAAAGCTACTTGGATAGGTGCAAGT
GGGGACCAAACTTTTTTACGAATTGATGAAGCACTTATTAATTCTCATGTACTTGCTACATCAGAAATTTTTGCCAGTAAACACATAATA
GGCTTGGTACCTGCTTCTATATCAGAACCTCCTCCATTTAAATGCCTTCTGATAAATAAAGTGGATGGGAGTTGTAAAACTTTTAATGAC
TCAGAACAAGAGGATCTGCAAGGATTTGGTGTGTGTCTTGATCCTGTATATGATGTAATTTGGAGGTTTCGACCAAATACTAGAGAGCTG
TGGTGTTACAATGCGGTGGTTGCTGATGCCAGGCTTCCCTCTGCAGCAGACATGCAGTCCAGATGTAGTATCCTAAGTCCTGAACTTGCC
TTACCAACAGGATCAAGGGCCCTCACTACCCGATCTCATGCAGCTTTGCACATTTTAGGTTGTCTTGATACCTTGGCAGCTATGCAGGAC
TTAAAAATGGGTGTTGCAAGTACAGAGGAAGAGACTCAAGCAGTAATGAAGGTTTATTCTAAAGAAGATTATAGTGTGGTAAACAGGTTT
GAAAGTCATGGAGGAGGCTGGGGTTATTCTGCCCATTCAGTAGAAGCTATACGTTTCAGTGCCGACACTGATATTTTACTTGGTGGTCTT
GGTCTGTTTGGAGGTAGAGGAGAATATACTGCTAAAATTAAGCTGTTTGAATTGGGTCCTGATGGAGGAGATCATGAAACTGATGGTGAC
CTTCTTGCAGAGACTGATGTATTGGCTTATGACTGTGCTGCTAGAGAAAAATATGCAATGATGTTTGATGAGCCTGTTCTCCTGCAAGCT
GGGTGGTGGTATGTGGCATGGGCCCGAGTGTCAGGACCCAGCAGTGACTGTGGATCTCATGGACAGGCATCTATTACCACAGATGATGGG
GTTGTTTTCCAGTTCAAGAGTTCAAAGAAATCAAATAATGGTACAGATGTTAATGCGGGTCAGATACCTCAGTTATTATACAGACTTCCA
ACCAGTGATGGCAGTGCTTCAAAAGGCAAACAGCAAACCAGTGAACCTGTACACATTTTAAAGAGGTCTTTTGCAAGAACTGTCTCAGTG
GAATGTTTTGAGTCATTGTTGAGTATTCTTCACTGGAGCTGGACCACCTTAGTCTTAGGAGTTGAAGAACTTAGAGGATTAAAAGGATTC
CAGTTCACAGCTACACTCCTAGATTTAGAGAGACTGCGCTTTGTGGGTACCTGTTGTCTGAGGTTATTGCGTGTCTATACCTGTGAAATT
TACCCAGTGTCAGCTACAGGAAAAGCAGTTGTAGAAGAAACTAGCAAATTAGCAGAGTGTATTGGAAAAACCAGAACTTTGTTAAGAAAA
ATTTTATCAGAAGGAGTTGATCACTGCATGGTGAAATTGGATAATGATCCTCAAGGATATCTCAGTCAACCCTTGAGTCTTCTAGAAGCT
GTCCTTCAGGAATGTCATAATACTTTCACTGCCTGCTTTCATTCTTTCTACCCAACTCCTGCCTTACAGTGGGCTTGCCTTTGTGATCTG
CTGAATTGTTTGGATCAGGATATCCAAGAAGCAAACTTCAAGACATCAAGTAGCCGACTCCTTGCAGCTGTTATGTCAGCTCTGTGTCAC
ACGTCTGTTAAGCTGACTTCCATCTTCCCGATTGCGTATGATGGAGAAGTATTACTACGATCAATTGTTAAACAAGTTAGTACAGAGAAC
GACTCAACACTAGTTCATCGTTTTCCCCTTTTGGTGGCACATATGGAAAAACTCAGCCAGAGTGAAGAGAATATCTCAGGGATGACAAGC
TTCCGTGAAGTTCTGGAGAAAATGCTGGTCATTGTTGTGCTACCAGTCAGGAACAGCCTGAGGAGAGAAAATGAACTCTTCTCCTCCCAC
CTCGTCTCTAACACCTGTGGATTACTGGCCAGCATTGTCAGTGAACTGACAGCGTCAGCCCTGGGATCTGAGGTTGATGGACTTAATTCT
CTTCACTCTGTAAAAGCTAGTGCTAACCGATTTACAAAAACAAGTCAGGGCAGAAGTTGGAACACTGGGAACGGGTCCCCTGATGCAATC
TGTTTTTCAGTAGACAAACCTGGAATAGTTGTGGTTGGTTTCTCTGTCTATGGAGGAGGTGGAATTCATGAATATGAATTAGAGGTGTTG
GTTGATGATAGTGAACATGCAGGAGATTCAACTCATTCCCACAGATGGACATCTCTGGAATTAGTGAAAGGAACGTACACAACGGATGAC
TCACCCAGTGATATAGCTGAGATCAGACTTGACAAAGTGGTTCCTTTAAAGGAAAATGTTAAATATGCTGTGCGCTTGAGGAACTATGGA
AGCCGTACAGCCAATGGAGATGGAGGAATGACCACAGTTCAGTGCCCTGATGGTGTGACATTCACATTCAGCACGTGCAGCTTGAGCAGT
AACGGCACAAACCAAACCAGAGGACAGATCCCACAGATACTCTACTATAGGAGTGAATTTGATGGAGATTTACAATCCCAACTTCTGAGT
AAAGCCAATGAAGAAGATAAAAACTGTAGCAGAGCATTGTCTGTTGTAAGCACTGTCGTTCGAGCCTCTAAGGACCTCCTGCACAGAGCT
CTTGCTGTGGATGCTGATGACATTCCAGAACTGCTGAGTTCTTCCAGTCTGTTTTCCATGCTGCTCCCCCTTATTATAGCCTACATAGGA
CCAGTAGCTGCTGCTATTCCCAAGGTGGCTGTAGAAGTCTTTGGCCTTGTCCAACAATTGCTTCCGTCAGTTGCCATTTTGAATCAGAAG
TATGCACCGCCTGCCTTCAACCCTAATCAGTCGACAGATAGCACCACAGGAAACCAGCCTGAACAGGGCCTCTCTGCTTGTACAACCTCC
AGTCACTATGCTGTCATAGAGAGTGAGCACCCGTATAAACCTGCCTGTGTGATGCATTACAAGGTGACATTCCCAGAATGTGTGAGGTGG
ATGACAATCGAATTTGACCCTCAGTGTGGTACTGCACAGTCAGAAGATGTCCTTCGTTTGTTGATTCCTGTCAGAACTGTTCAGAATTCA
GGATATGGACCAAAATTGACATCTGTTCATGAAAATCTTAATTCATGGATAGAATTAAAGAAATTTTCAGGATCCTCTGGGTGGCCTACT
ATGGTTTTGGTGTTGCCAGGAAATGAGGCCCTTTTTTCATTGGAGACTGCATCAGATTATGTGAAAGATGACAAAGCTTCTTTCTATGGT
TTTAAGTGTTTTGCAATTGGATATGAATTTAGCCCTGGACCTGATGAGGGAGTCATCCAATTGGAAAAAGAATTAGCCAATCTTGGTGGG
GTTTGTGCAGCAGCTCTGATGAAGAAGGACCTAGCACTTCCTATTGGTAATGAATTAGAAGAAGACCTTGAAATTCTTGAGGAGGCTGCA
TTGCAGGTGTGCAAAACCCATTCTGGAATTCTTGGAAAGGGTCTAGCTCTTTCTCATTCACCAACTATATTAGAAGCACTTGAGGGAAAT
TTACCACTCCAAATCCAAAGCAATGAACAGTCTTTTCTGGATGATTTTATTGCCTGTGTCCCAGGATCAAGTGGTGGAAGGCTTGCAAGG
TGGCTTCAGCCAGATTCATATGCGGATCCTCAGAAAACATCTTTGATCCTGAATAAGGATGATATTCGTTGTGGTTGGCCTACCACCATA
ACTGTTCAAACAAAAGACCAGTATGGGGATGTGGTACATGTTCCCAATATGAAGGTGGAAGTGAAAGCTGTCCCTGTTTCTCAGAAAAAA
ATGTCTTTACAACAAGATCAAGCAAAGAAACCTCAAAGGATTCCTGGCAGTCCTGCAGTAACAGCTGCATCTTCTAATACTGACATGACT
TATGGAGGGCTGGCATCACCAAAGCTAGATGTTTCATATGAACCAATGATAGTGAAGGAAGCTCGATATATTGCCATAACAATGATGAAG
GTTTATGAAAATTATTCATTTGAAGAACTACGTTTTGCATCACCAACTCCTAAGAGACCCAGTGAGAATATGCTGATCCGTGTCAATAAT
GATGGGACTTATTGTGCAAATTGGACTCCAGGGGCTATTGGACTCTACACTCTTCATGTTACCATTGATGGCATTGAAATCGATGCTGGT
CTGGAAGTAAAAGTAAAAGACCCACCAAAAGGGATGATACCACCAGGAACTCAGTTGGTCAAACCAAAGTCTGAACCTCAGCCTAATAAG
GTTCGAAAATTTGTGGCCAAGGACAGTGCGGGGCTTCGCATCCGTAGCCACCCTTCCCTTCAGAGTGAGCAGATAGGCATAGTGAAAGTC
AATGGAACTATCACTTTTATTGATGAGATCCATAATGATGATGGTGTGTGGCTGAGGCTGAATGATGAGACAATAAAGAAGTATGTCCCT
AACATGAATGGTTACACTGAAGCCTGGTGCCTCTCTTTTAATCAACATCTTGGCAAGAGTCTTCTGGTCCCTGTTGACGAATCTAAAACT
AATACTGATGACTTTTTCAAAGACATAAACTCCTGCTGCCCACAGGAAGCAACAATGCAAGAACAAGATATGCCATTCTTGCGAGGAGGG
CCAGGCATGTACAAGGTAGTGAAGACGGGACCTTCAGGTCACAACATCAGAAGCTGCCCTAACCTTAGAGGTATCCCAATTGGAATGTTA
GTTCTGGGAAACAAAGTCAAAGCAGTGGGAGAGGTAACCAATTCTGAAGGGACATGGGTGCAACTGGATCAGAACAGCATGGTAGAGTTC
TGTGAGAGTGATGAAGGAGAGGCATGGTCCTTAGCTAGAGACAGAGGCGGAAACCAGTACCTCCGACATGAAGATGAACAAGCTCTTCTG
GATCAGAATTCTCAAACTCCTCCTCCAAGCCCTTTCTCAGTGCAAGCTTTTAATAAAGGGGCAAGTTGCAGTGCCCAAGGATTTGATTAT
GGACTCGGAAATAGCAAAGGTGATCGAGGAAACATCTCAACATCTTCTAAACCAGCCTCTACATCAGGAAAATCAGAGCTGTCCTCTAAA
CACAGCAGATCGCTTAAACCTGATGGACGTATGAGCCGGACTACTGCTGATCAGAAGAAGCCAAGGGGCACAGAAAGTTTATCTGCTAGT
GAATCCCTCATCTTAAAATCTGATGCTGCAAAGTTGAGGTCAGATTCCCACAGTAGGTCATTATCCCCCAACCATAACACCTTGCAGACA
TTGAAATCTGATGGGAGGATGCCTTCTAGCTCCAGAGCTGAATCCCCAGGACCAGGTTCTCGGTTGTCATCTCCTAAGCCAAAGACTCTC
CCAGCCAATAGGTCTAGCCCATCGGGTGCTAGTTCTCCACGCTCCTCCTCACCACATGATAAAAATCTACCTCAAAAAAGTACTGCTCCT
GTTAAGACAAAGCTTGATCCTCCTCGGGAACGTTCTAAATCAGACTCTTACACACTTGATCCAGATACCCTCCGCAAGAAGAAAATGCCC
CTCACAGAACCTTTGAGAGGACGGTCAACGTCACCAAAACCAAAATCAGTACCAAAGGATTCTACAGATTCCCCTGGATCTGAAAATAGA
GCTCCCTCTCCCCATGTGGTACAGGAAAACCTCCACAGTGAGGTGGTCGAAGTCTGCACCTCAAGTACTTTAAAAACAAATAGTCTAACA
GACAGCACCTGCGATGACAGCAGTGAATTTAAGAGTGTGGATGAAGGTTCAAATAAAGTTCATTTTAGCATTGGAAAAGCACCACTGAAA
GATGAACAGGAAATGAGAGCATCTCCCAAAATAAGTCGAAAATGTGCTAATAGACACACCAGGCCCAAAAAAGAAAAATCGAGTTTTCTT
TTCAAAGGAGATGGATCCAAGCCTTTAGAGCCAGCCAAGCAAGCCATGTCTCCTTCTGTGGCCGAATGTGCCAGAGCTGTGTTTGCTTCC
TTCCTCTGGCATGAAGGCATAGTACATGATGCAATGGCTTGTTCTTCTTTCCTAAAGTTTCATCCTGAACTTTCCAAAGAACATGCTCCT
ATAAGGAGTAGTTTAAATAGCCAACAACCTACAGAGGAAAAAGAAACCAAGTTAAAAAATAGACATTCATTAGAAATATCATCTGCACTG
AATATGTTTAATATTGCACCCCATGGACCAGATATATCTAAGATGGGTAGCATCAACAAAAACAAGGTATTGTCTATGCTTAAGGAACCA
CCTCTGCATGAAAAATGTGAGGATGGGAAAACCGAGACCACTTTTGAAATGTCCATGCATAACACAATGAAGTCTAAGTCTCCTCTTCCC
TTAACTTTACAACATTTAGTGGCTTTTTGGGAAGACATCTCTTTGGCTACTATCAAAGCTGCTTCCCAGAATATGATTTTTCCAAGTCCT
GGTTCCTGTGCAGTTCTTAAAAAGAAAGAGTGTGAGAAAGAGAATAAGAAGTCCAAAAAGGAAAAAAAGAAAAAAGAAAAGGCAGAAGTT
AGGCCCAGGGGTAATTTGTTTGGAGAGATGGCCCAGCTGGCAGTAGGAGGACCAGAGAAAGATACCATCTGTGAACTGTGTGGGGAGTCA
CATCCATACCCGGTGACCTATCACATGAGACAAGCTCACCCAGGTTGTGGCCGATATGCTGGTGGACAAGGTTACAATAGCATTGGGCAT
TTTTGTGGAGGATGGGCTGGTAACTGTGGTGATGGTGGCATAGGAGGAAGCACTTGGTATCTGGTATGTGATCGCTGTAGAGAAAAATAC
CTCCGCGAAAAACAGGCTGCTGCAAGGGAGAAGGTCAAACAATCTAGGAGAAAACCAATGCAAGTCAAGACCCCTCGTGCCTTGCCCACC
ATGGAAGCTCACCAGGTGATTAAAGCCAATGCACTCTTCCTGCTGTCCCTGAGCAGTGCAGCAGAACCGAGCATTCTGTGTTACCATCCT
GCAAAGCCATTCCAATCTCAGTTGCCCAGTGTAAAAGAAGGCATTTCTGAGGATCTTCCTGTGAAAATGCCTTGTCTCTACCTGCAGACA
TTAGCTAGGCATCATCATGAAAATTTTGTGGGCTATCAAGATGACAATCTATTCCAGGATGAAATGAGATATCTACGTTCAACATCTGTA
CCTGCCCCGTATATATCAGTAACTCCTGATGCAAGTCCTAATGTATTTGAAGAGCCAGAGAGCAATATGAAGTCTATGCCACCAAGTTTA
GAAACCAGTCCCATAACTGATACTGATCTTGCAAAGAGAACTGTCTTCCAAAGATCATACTCAGTTGTTGCTTCCGAATATGATAAACAA
CACTCCATTTTACCTGCACGAGTTAAAGCTATTCCTAGAAGAAGAGTTAACAGTGGAGACACTGAAGTTGGTTCTTCCCTTTTGAGACAT
CCGTCTCCTGAGCTTTCTCGGCTAATCTCAGCCCACAGCTCTCTTTCTAAAGGAGAACGAAATTTCCAGTGGCCAGTTTTAGCTTTTGTT
ATACAACATCATGATCTAGAAGGTCTTGAAATAGCAATGAAACAGGCCCTAAGGAAATCTGCTTGTCGAGTTTTTGCTATGGAGGCTTTC
AACTGGCTTCTGTGTAATGTCATCCAAACCACTTCTCTCCATGATATTCTGTGGCATTTTGTGGCATCACTGACTCCTGCACCAGTGGAA
CCAGAGGAAGAAGAGGATGAAGAAAATAAAACAAGCAAAGAAAATTCAGAACAATTTATGTTATGATAGCAATTTTCTGCATAGCATCAG
CAATGAGTCTGTACAACTGTCTTGCTGCACTAATTCATAAGATACCATATGGACAATGCACGATTGCATGTCGTGGCAAAAACATGGAAG
TGAGACTTATTTTTCTCTCTGGACTGTGCATAGCAGTAGCTGTTGTTTGGGCTGTGTTTCGAAATGAAGACAGGTGGGCTTGGATTTTAC
AGGATATCTTGGGGATTGCTTTCTGTCTGAATTTAATTAAAACACTGAAGTTGCCCAACTTCAAGTCATGTGTGATACTTCTAGGCCTTC
TCCTCCTCTATGATGTATTTTTTGTTTTCATAACACCATTCATCACAAAGAATGGTGAGAGTATCATGGTTGAACTCGCAGCTGGACCTT
TTGGAAATAATGAAAAGTTGCCAGTAGTCATCAGAGTACCAAAACTGATCTATTTCTCAGTAATGAGTGTGTGCCTCATGCCTGTTTCAA
TATTGGGTTTTGGAGACATTATTGTACCAGGCCTGTTGATTGCATACTGTAGAAGATTTGATGTTCAGACTGGTTCTTCTTACATATACT
ATGTTTCGTCTACAGTTGCCTATGCTATTGGCATGATACTTACATTTGTTGTTCTGGTGCTGATGAAAAAGGGGCAACCTGCTCTCCTCT
ATTTAGTACCTTGCACACTTATTACTGCCTCAGTTGTTGCCTGGAGACGTAAGGAAATGAAAAAGTTCTGGAAAGGTAACAGCTATCAGA
TGATGGACCATTTGGATTGTGCAACAAATGAAGAAAACCCTGTGATATCTGGTGAACAGATTGTCCAGCAATAATATTATGTGGAACTGC
TATAATGTGTCATTGATTTTCTACAAATAGACTTCGACTTTTTAAATTGACTTTTGAATTGACAATCTGAAAGAGTCTTCAATGATATGC
TTGCAAAAATATATTTTTATGAGCTGGTACTGACAGTTACATCATAAATAACTAAAACGCTTTGCTTTTAATGTTAAAGTTGTGCCTTCA
CATTAAATAAAACATATGGTCTGTGTAGTTTCCGAGATGTACTATATACAGTATATTTTTCTAAAAAAAAATGCCTTGACCCACCCCTAT
ACTTTTTTTTAACGAAATCTGTTTCTTTCAGCTCTGATGGTAGATACAAGTAGTTACTATTTCTGAATGGGTTTTACTGTAAAGAATTAT
GCAAATTGGCCAGGCGCGGTGGCTCACGCCTGTAATCCCAACACTTTGGGAGGCCAAGGCGGGCGGATCACGAGGTCAGGAGATCGAGAC

>56210_56210_1_MYCBP2-SPPL2A_MYCBP2_chr13_77661619_ENST00000357337_SPPL2A_chr15_51028937_ENST00000261854_length(amino acids)=3592AA_BP=
MFMPVPDGSVAAAGLGLGLPAADSRGHYQLLLSGRALADRYRRIYTAALNDRDQGGGSAGHPASRNKKILNKKKLKRKQKSKSKVKTRSK
SENLENTVIIPDIKLHSNPSAFNIYCNVRHCVLEWQKKEISLAAASKNSVQSGESDSDEEEESKEPPIKLPKIIEVGLCEVFELIKETRF
SHPSLCLRSLQALLNVLQGQQPEGLQSEPPEVLESLFQLLLEITVRSTGMNDSTGQSLTALSCACLFSLVASWGETGRTLQAISAILTNN
GSHACQTIQVPTILNSLQRSVQAVLVGKIQIQDWFSNGIKKAALMHKWPLKEISVDEDDQCLLQNDGFFLYLLCKDGLYKIGSGYSGTVR
GHIYNSTSRIRNRKEKKSWLGYAQGYLLYRDVNNHSMTAIRISPETLEQDGTVMLPDCHTEGQNILFTDGEYINQIAASRDDGFVVRIFA
TSTEPVLQQELQLKLARKCLHACGISLFDLEKDLHIISTGFDEESAILGAGREFALMKTANGKIYYTGKYQSLGIKQGGPSAGKWVELPI
TKSPKIVHFSVGHDGSHALLVAEDGSIFFTGSASKGEDGESTKSRRQSKPYKPKKIIKMEGKIVVYTACNNGSSSVISKDGELYMFGKDA
IYSDSSSLVTDLKGHFVTQVAMGKAHTCVLMKNGEVWTFGVNNKGQCGRDTGAMNQGGKGFGVENMATAMDEDLEEELDEKDEKSMMCPP
GMHKWKLEQCMVCTVCGDCTGYGASCVSSGRPDRVPGGICGCGSGESGCAVCGCCKACARELDGQEARQRGILDAVKEMIPLDLLLAVPV
PGVNIEEHLQLRQEEKRQRVIRRHRLEEGRGPLVFAGPIFMNHREQALARLRSHPAQLKHKRDKHKDGSGERGEKDASKITTYPPGSVRF
DCELRAVQVSCGFHHSVVLMENGDVYTFGYGQHGQLGHGDVNSRGCPTLVQALPGPSTQVTAGSNHTAVLLMDGQVFTFGSFSKGQLGRP
ILDVPYWNAKPAPMPNIGSKYGRKATWIGASGDQTFLRIDEALINSHVLATSEIFASKHIIGLVPASISEPPPFKCLLINKVDGSCKTFN
DSEQEDLQGFGVCLDPVYDVIWRFRPNTRELWCYNAVVADARLPSAADMQSRCSILSPELALPTGSRALTTRSHAALHILGCLDTLAAMQ
DLKMGVASTEEETQAVMKVYSKEDYSVVNRFESHGGGWGYSAHSVEAIRFSADTDILLGGLGLFGGRGEYTAKIKLFELGPDGGDHETDG
DLLAETDVLAYDCAAREKYAMMFDEPVLLQAGWWYVAWARVSGPSSDCGSHGQASITTDDGVVFQFKSSKKSNNGTDVNAGQIPQLLYRL
PTSDGSASKGKQQTSEPVHILKRSFARTVSVECFESLLSILHWSWTTLVLGVEELRGLKGFQFTATLLDLERLRFVGTCCLRLLRVYTCE
IYPVSATGKAVVEETSKLAECIGKTRTLLRKILSEGVDHCMVKLDNDPQGYLSQPLSLLEAVLQECHNTFTACFHSFYPTPALQWACLCD
LLNCLDQDIQEANFKTSSSRLLAAVMSALCHTSVKLTSIFPIAYDGEVLLRSIVKQVSTENDSTLVHRFPLLVAHMEKLSQSEENISGMT
SFREVLEKMLVIVVLPVRNSLRRENELFSSHLVSNTCGLLASIVSELTASALGSEVDGLNSLHSVKASANRFTKTSQGRSWNTGNGSPDA
ICFSVDKPGIVVVGFSVYGGGGIHEYELEVLVDDSEHAGDSTHSHRWTSLELVKGTYTTDDSPSDIAEIRLDKVVPLKENVKYAVRLRNY
GSRTANGDGGMTTVQCPDGVTFTFSTCSLSSNGTNQTRGQIPQILYYRSEFDGDLQSQLLSKANEEDKNCSRALSVVSTVVRASKDLLHR
ALAVDADDIPELLSSSSLFSMLLPLIIAYIGPVAAAIPKVAVEVFGLVQQLLPSVAILNQKYAPPAFNPNQSTDSTTGNQPEQGLSACTT
SSHYAVIESEHPYKPACVMHYKVTFPECVRWMTIEFDPQCGTAQSEDVLRLLIPVRTVQNSGYGPKLTSVHENLNSWIELKKFSGSSGWP
TMVLVLPGNEALFSLETASDYVKDDKASFYGFKCFAIGYEFSPGPDEGVIQLEKELANLGGVCAAALMKKDLALPIGNELEEDLEILEEA
ALQVCKTHSGILGKGLALSHSPTILEALEGNLPLQIQSNEQSFLDDFIACVPGSSGGRLARWLQPDSYADPQKTSLILNKDDIRCGWPTT
ITVQTKDQYGDVVHVPNMKVEVKAVPVSQKKMSLQQDQAKKPQRIPGSPAVTAASSNTDMTYGGLASPKLDVSYEPMIVKEARYIAITMM
KVYENYSFEELRFASPTPKRPSENMLIRVNNDGTYCANWTPGAIGLYTLHVTIDGIEIDAGLEVKVKDPPKGMIPPGTQLVKPKSEPQPN
KVRKFVAKDSAGLRIRSHPSLQSEQIGIVKVNGTITFIDEIHNDDGVWLRLNDETIKKYVPNMNGYTEAWCLSFNQHLGKSLLVPVDESK
TNTDDFFKDINSCCPQEATMQEQDMPFLRGGPGMYKVVKTGPSGHNIRSCPNLRGIPIGMLVLGNKVKAVGEVTNSEGTWVQLDQNSMVE
FCESDEGEAWSLARDRGGNQYLRHEDEQALLDQNSQTPPPSPFSVQAFNKGASCSAQGFDYGLGNSKGDRGNISTSSKPASTSGKSELSS
KHSRSLKPDGRMSRTTADQKKPRGTESLSASESLILKSDAAKLRSDSHSRSLSPNHNTLQTLKSDGRMPSSSRAESPGPGSRLSSPKPKT
LPANRSSPSGASSPRSSSPHDKNLPQKSTAPVKTKLDPPRERSKSDSYTLDPDTLRKKKMPLTEPLRGRSTSPKPKSVPKDSTDSPGSEN
RAPSPHVVQENLHSEVVEVCTSSTLKTNSLTDSTCDDSSEFKSVDEGSNKVHFSIGKAPLKDEQEMRASPKISRKCANRHTRPKKEKSSF
LFKGDGSKPLEPAKQAMSPSVAECARAVFASFLWHEGIVHDAMACSSFLKFHPELSKEHAPIRSSLNSQQPTEEKETKLKNRHSLEISSA
LNMFNIAPHGPDISKMGSINKNKVLSMLKEPPLHEKCEDGKTETTFEMSMHNTMKSKSPLPLTLQHLVAFWEDISLATIKAASQNMIFPS
PGSCAVLKKKECEKENKKSKKEKKKKEKAEVRPRGNLFGEMAQLAVGGPEKDTICELCGESHPYPVTYHMRQAHPGCGRYAGGQGYNSIG
HFCGGWAGNCGDGGIGGSTWYLVCDRCREKYLREKQAAAREKVKQSRRKPMQVKTPRALPTMEAHQVIKANALFLLSLSSAAEPSILCYH
PAKPFQSQLPSVKEGISEDLPVKMPCLYLQTLARHHHENFVGYQDDNLFQDEMRYLRSTSVPAPYISVTPDASPNVFEEPESNMKSMPPS
LETSPITDTDLAKRTVFQRSYSVVASEYDKQHSILPARVKAIPRRRVNSGDTEVGSSLLRHPSPELSRLISAHSSLSKGERNFQWPVLAF

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for MYCBP2-SPPL2A

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for MYCBP2-SPPL2A

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for MYCBP2-SPPL2A

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source